<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/674868E7-57F1-456D-B8F6-C92B04571851"><gtr:id>674868E7-57F1-456D-B8F6-C92B04571851</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Bayliss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800021"><gtr:id>DC3C0DD0-A9C7-4054-A7BD-03D802DBA08F</gtr:id><gtr:title>Structural studies on phospho-regulation of the TACC3 / ChTOG protein complex in mitotic spindle assembly</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800021</gtr:grantReference><gtr:abstractText>Viewed through a microscope, cells undergo a spectacular transformation as they enter mitosis, the phase of their existence just before they divide. The formation of the mitotic spindle, where the cell?s network of microtubule fibres is completely rearranged to span from either end to the chromosomes at the centre, is particularly striking. This spindle is a molecular machine that ensures the cell?s chromosomes are accurately distributed between its two daughter cells. Errors in the workings of the spindle are a known driving force of cancer and are also responsible for a congenital brain disease. Several control mechanisms ensure the mitotic spindle is normally assembled correctly. At an early stage in assembly, two proteins called TACC3 and ChTOG promote microtubule stability and hence promote assembly. These proteins are more effective when TACC3 is modified by a phosphate group: one phosphorous atom and three oxygen atoms that is commonly used by cells to alter the activity of their proteins. In the case of TACC3, the protein that adds the phosphate is called Aurora-A. Spindle assembly is thus controlled by the activity of Aurora-A, which is itself controlled by many other proteins under the influence of events within and outside the cell. We propose to investigate how the phosphate group influences the effectiveness of the TACC3/ChTOG partnership at the level of atoms. How this works is currently a mystery as the phosphate is only four atoms big, and yet it changes the activity of TACC3/ChTOG which total tens of thousands of atoms. We will use electron microscopy, a technique that allows us to see directly the shapes of proteins, to study the changes in TACC3 upon phosphorylation, and the effect on ChTOG. We will also use X-ray crystallography to determine the location of every atom within the proteins and to map the atoms by which TACC3 and ChTOG cooperate. This information will allow us to make a hypothesis for the details of how the TACC3/ChTOG partnership works and how phosphorylation enhances their effectiveness. We will use our protein structure models to design subtle modifications to TACC3 and ChTOG to test this hypothesis in human cells grown in culture. An overabundance of TACC3, ChTOG or Aurora-A have been linked with cancer, and TACC3 and Aurora-A are also important in brain development. These studies will provide the impetus for future investigations to understand the role of these proteins in human disease.</gtr:abstractText><gtr:technicalSummary>At the entry to mitosis microtubules assemble into a bipolar mitotic spindle, a molecular machine for the accurate segregation of chromosomes in cell division. Improper mitotic spindle function is a driver of carcinogenesis and is implicated in autosomal recessive primary microcephaly, a congenital brain disease. Mitotic spindle assembly is mediated by the interactions of microtubules with many scaffolding and motor proteins. These interactions are regulated by protein kinases. For example, the conserved assembly-promoting TACC3 / ChTOG protein complex is regulated by Aurora-A kinase. Phosphorylation of TACC3 by Aurora-A enhances the centrosomal localisation of the protein and increases the assembly-promoting activity of ChTOG. We propose to determine the structural mechanism of TACC3 / ChTOG phospho-regulation by Aurora-A and verify the mechanism in human tissue culture cells. The first aim of our proposal is to address whether Aurora-A induces a conformational change in TACC3, and deduce the nature of the change. We will apply biochemical and biophysical techniques such as circular dichroism spectroscopy, analytical ultracentrifugation and multi-angle light scattering to compare the structure and oligomerisation state of phosphorylated and unphosphorylated TACC3. We plan to solve the TACC3 structure using X-ray crystallography. Our second aim is to determine the structural basis of the TACC3/ChTOG interaction and devise a model for the mechanism of ChTOG regulation by TACC3. We will use X-ray crystallography to determine a high resolution structure of the minimal TACC3 / ChTOG complex. We will use electron microscopy to visualise longer fragments of the proteins, and place the high resolution structure in the context of the longer proteins. Electron microscopy data will be analysed to define structural changes upon complex formation and/or phosphorylation. Putting this information together, we will devise a structural model for the mechanisms of TACC3 / ChTOG regulation and function. Our third aim is to validate the structural mechanisms and models in human tissue culture cells. Our structural studies will inform the design of fragments or point mutants of TACC3 and ChTOG to interfere with their function and regulation. We will use these mutants to test our structural models in human tissue culture cells, a model system in which TACC3 / ChTOG function and regulation is poorly understood. Notably, overexpression of all three proteins has been linked with cancer. The structural mechanisms, models and reagents we produce will be invaluable in understanding the role of these proteins in human disease.</gtr:technicalSummary><gtr:fund><gtr:end>2011-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>391328</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Biomedical Cell Biology</gtr:department><gtr:description>Cell biology of TACC/ch-TOG complexes</gtr:description><gtr:id>C204388D-E969-4E47-9FF8-9CEA3003F7C7</gtr:id><gtr:impact>We have submitted a paper together as co-authors, the paper was published in 2013.</gtr:impact><gtr:outcomeId>qTawNEBjycq-2</gtr:outcomeId><gtr:partnerContribution>They have carried out cell biology experiments based on our reagents and ideas.</gtr:partnerContribution><gtr:piContribution>We have provided our collaborator with novel reagents to carry out their studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>M. D. Anderson Cancer Center</gtr:department><gtr:description>MD Anderson</gtr:description><gtr:id>5F4DDC75-1709-449E-8D81-F98C9D00E5A5</gtr:id><gtr:impact>19925808</gtr:impact><gtr:outcomeId>F6BFFC6B552-1</gtr:outcomeId><gtr:partnerContribution>My collaborator has engineered a mouse with the Mcph1 gene knocked out. He uses cells derived from this system to carry out functional assays on the Mcph1 protein and mutants of Mcph1. For our recent publication, he used the system to verify the prediction we made concerning the functional importance of a pocket on the surface of the Mcph1 protein.</gtr:partnerContribution><gtr:piContribution>We determined the X-ray crystal structure of the first BRCT repeat domain of Mcph1, which guided our collaborators cell biology experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences KCL</gtr:department><gtr:description>NMR studies on CHTOG</gtr:description><gtr:id>B3D3023F-0DB6-4D74-B4D2-D0E1FE8FE017</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>Mou45dETq7k-1</gtr:outcomeId><gtr:partnerContribution>We have been unable to crystallize CHTOG proteins. The collaboration with Mark Pfuhl has revealed which of the proteins is the most suitable for further structural studies. We hope that the insights will enable us to crystallize the protein, or will result in structure determination by NMR.</gtr:partnerContribution><gtr:piContribution>We have provided the biological question and the reagents with which to carry out the experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cellular and Molecular Physiology</gtr:department><gtr:description>Cell biology of TACC/ch-TOG complexes</gtr:description><gtr:id>AB53AC7F-FBA8-48BF-8BE1-6B6D56937E66</gtr:id><gtr:impact>We have submitted a paper together as co-authors, the paper was published in 2013.</gtr:impact><gtr:outcomeId>qTawNEBjycq-1</gtr:outcomeId><gtr:partnerContribution>They have carried out cell biology experiments based on our reagents and ideas.</gtr:partnerContribution><gtr:piContribution>We have provided our collaborator with novel reagents to carry out their studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Studies on mitosis using DT40 cells</gtr:description><gtr:id>86003BCB-EAF2-4474-8193-4CBDE75FC9E5</gtr:id><gtr:impact>We have a manuscript of a research article under review.</gtr:impact><gtr:outcomeId>54627fb73602b1.04767124-1</gtr:outcomeId><gtr:partnerContribution>My collaborators in Cambridge use DT40 cells to knock in mutations and carry out cell biology studies.</gtr:partnerContribution><gtr:piContribution>Biochemical and structural studies led to the design of mutant proteins with altered functions.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press releases to mark the publication of our 2013 JCB paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>697DCC44-16C1-43B8-B2AA-460A43C4B4A8</gtr:id><gtr:impact>Press releases were issued by the University of Leicester and the University of Warwick. Our paper was featured on the Cancer Research UK science blog.

None.</gtr:impact><gtr:outcomeId>Aqzh6H13R4d</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://scienceblog.cancerresearchuk.org/2013/08/14/mitotic-spindles-could-help-develop-better-chemo-drugs/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>653461</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant, Responsive Mode</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L023113/1</gtr:fundingRef><gtr:id>939C48BA-5AF6-47FA-B196-8FE042711994</gtr:id><gtr:outcomeId>5461ec100c5913.51999178</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>724254</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biological Sciences Committee - Programme Award</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C24461/A12772</gtr:fundingRef><gtr:id>AD8C1F71-2767-4B85-A278-0CC30F1EE8E5</gtr:id><gtr:outcomeId>V6QUpiY5Rqj0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have designed point mutants of TACC3 that specifically interfere with its interaction with ch-TOG. These reagents are not available from other laboratories.</gtr:description><gtr:id>1E476EE0-CD88-45E4-8409-F98F4613471B</gtr:id><gtr:impact>Manuscript under review.</gtr:impact><gtr:outcomeId>dMsP5PAy7Bz</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mutants of TACC3 that disrupt binding to ch-TOG</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have designed point mutants of TACC3 that prevent its interaction with Aurora-A.</gtr:description><gtr:id>FCBFCC24-E12B-4D66-998F-423C662C9934</gtr:id><gtr:impact>Manuscript in preparation.</gtr:impact><gtr:outcomeId>ShBiEti6poL</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mutants of TACC3 that interfere with Aurora-A interaction</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F4F28AC2-2669-4EE3-84ED-6E2B4B320132</gtr:id><gtr:title>Mitotic spindle association of TACC3 requires Aurora-A-dependent stabilization of a cryptic a-helix.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff61c4ed2668f5f982988d739a12757"><gtr:id>2ff61c4ed2668f5f982988d739a12757</gtr:id><gtr:otherNames>Burgess SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>5aa022f4e1a806.96739991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F5F4F2C-9CD9-45AA-9704-E20ADF392864</gtr:id><gtr:title>Solution NMR assignment of the cryptic sixth TOG domain of mini spindles.</gtr:title><gtr:parentPublicationTitle>Biomolecular NMR assignments</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff61c4ed2668f5f982988d739a12757"><gtr:id>2ff61c4ed2668f5f982988d739a12757</gtr:id><gtr:otherNames>Burgess SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1874-270X</gtr:issn><gtr:outcomeId>5675e4660f815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>823DA2A2-C8FB-45E0-8F7B-D79EA27C4800</gtr:id><gtr:title>Coordination of adjacent domains mediates TACC3-ch-TOG-clathrin assembly and mitotic spindle binding.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b0ffcf175823e4efb6c24b3e27511d8"><gtr:id>9b0ffcf175823e4efb6c24b3e27511d8</gtr:id><gtr:otherNames>Hood FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>doi_53cd4ed4ef8c895e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8BE1085-5C75-476D-AD2A-B1A2C8CEB8CA</gtr:id><gtr:title>A pocket on the surface of the N-terminal BRCT domain of Mcph1 is required to prevent abnormal chromosome condensation.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b98a5bf929ac5dba2d141e7bd0985e3"><gtr:id>9b98a5bf929ac5dba2d141e7bd0985e3</gtr:id><gtr:otherNames>Richards MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>B7953B7029D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>152EC067-C56D-44D2-B1A8-CE377ECF9EBA</gtr:id><gtr:title>Aurora-A-Dependent Control of TACC3 Influences the Rate of Mitotic Spindle Assembly.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff61c4ed2668f5f982988d739a12757"><gtr:id>2ff61c4ed2668f5f982988d739a12757</gtr:id><gtr:otherNames>Burgess SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>5675e7b943e33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E62153BD-2EFF-4DDC-BCCA-88C73F2FEC67</gtr:id><gtr:title>An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b98a5bf929ac5dba2d141e7bd0985e3"><gtr:id>9b98a5bf929ac5dba2d141e7bd0985e3</gtr:id><gtr:otherNames>Richards MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>47D4DD68079</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800021</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>